Management of Hemorrhagic Cystitis
For chemotherapy-induced hemorrhagic cystitis, prevention with mesna is the cornerstone: administer 20% of the ifosfamide dose IV initially, followed by oral mesna at 40% of the ifosfamide dose at 2 and 6 hours after each ifosfamide dose, and for established hemorrhagic cystitis, initiate a stepwise escalation from conservative bladder irrigation through intravesical therapies to invasive interventions based on bleeding severity.
Prevention (Chemotherapy-Associated)
Ifosfamide-Induced Hemorrhagic Cystitis
Mesna is FDA-approved and strongly recommended for preventing hemorrhagic cystitis in patients receiving ifosfamide chemotherapy 1:
- Initial IV dose: 20% of the ifosfamide dose (weight/weight) given as IV bolus at the time of ifosfamide administration
- Oral maintenance: Mesna tablets 40% of the ifosfamide dose given orally at 2 hours and 6 hours after each ifosfamide dose
- Total daily mesna dose: 100% of the ifosfamide dose
- Important caveat: If the patient vomits within 2 hours of taking oral mesna, repeat the oral dose or switch to IV mesna 1
This IV-oral-oral regimen demonstrated <5% incidence of grade 3-4 hematuria and has a safety profile equivalent to all-IV regimens 1.
Cyclophosphamide-Induced Hemorrhagic Cystitis
Mesna plus saline diuresis or forced saline diuresis alone is recommended to decrease urothelial toxicity with high-dose cyclophosphamide, particularly in stem-cell transplantation settings 1.
Treatment of Established Hemorrhagic Cystitis
Initial Conservative Management
The first priority is hemodynamic stabilization and establishing adequate bladder drainage 2, 3, 4:
- Bladder drainage: Insert large-bore (22-24 Fr) three-way urethral catheter
- Manual clot evacuation: Remove existing clots to prevent catheter obstruction
- Continuous bladder irrigation: Use normal saline to maintain clear or light pink urine output
- Hydration: Aggressive IV fluid resuscitation if hemodynamically unstable
Escalation Algorithm for Persistent Bleeding
When conservative measures fail after 24-48 hours, proceed systematically 5, 3, 4, 6:
Step 1: Operative Cystoscopy
- Perform cystoscopy with clot evacuation under anesthesia
- Fulguration of bleeding vessels using electrocautery or laser ablation
- This provides both diagnostic information and therapeutic benefit
Step 2: Intravesical Therapies (in order of preference)
First-line intravesical agents 3, 4, 6:
- Alum (1% solution): Continuous bladder irrigation at 250-300 mL/hour for 24-72 hours; causes protein precipitation and capillary vasoconstriction
- Aminocaproic acid: Inhibits fibrinolysis; use as continuous irrigation
Second-line intravesical agents:
- Prostaglandins: Anti-inflammatory effects on bladder mucosa
- Silver nitrate (0.5-1% solution): Use with extreme caution due to potential for bladder fibrosis and contracture
Last-line intravesical therapy:
- Formalin (1-10% solution): Reserved for refractory cases due to caustic effects on bladder mucosa; requires general anesthesia and may cause irreversible bladder damage 3, 4
- Must protect upper tracts with ureteral catheters or nephrostomy tubes before formalin instillation
Step 3: Non-Intravesical Systemic Therapies
Hyperbaric oxygen therapy (HBO) 5, 3, 6:
- Particularly effective for radiation-induced hemorrhagic cystitis
- Promotes neovascularization and tissue healing
- Typical protocol: 90-120 minutes at 2.0-2.5 atmospheres absolute pressure, 20-40 sessions
- Success rates vary but can achieve resolution in 75-85% of radiation cystitis cases
Oral pentosan polysulfate: May provide symptomatic relief through bladder surface glycosaminoglycan layer restoration 3
Step 4: Interventional Procedures
When medical management fails 3, 4:
Superselective angioembolization:
- Target anterior division of internal iliac artery
- Preserves bladder function while controlling hemorrhage
- Success rate approximately 70-80% for acute control
Percutaneous nephrostomy tubes:
- Bilateral placement to divert urine and allow bladder rest
- Particularly useful when planning formalin instillation or if bladder irrigation is ineffective
Step 5: Definitive Surgical Management
Cystectomy with urinary diversion is the last resort for life-threatening, refractory hemorrhagic cystitis 3, 4:
- Reserved for patients failing all other therapies
- Associated with significant morbidity and mortality, especially in debilitated patients
- Requires careful patient selection and shared decision-making
Special Considerations
Radiation-Induced Hemorrhagic Cystitis
The pathophysiology differs from chemotherapy-induced cystitis (fibrosis and vascular remodeling vs. direct acrolein toxicity) 5, 2, 6. HBO therapy is particularly effective for radiation cystitis and should be considered earlier in the treatment algorithm 6.
BK Virus-Associated Hemorrhagic Cystitis (Post-Transplant)
This occurs primarily after allogeneic hematopoietic stem cell transplantation 7, 8:
- Supportive care remains the foundation
- Consider intravesical cidofovir for direct antiviral effect on bladder mucosa
- Immunomodulation by reducing immunosuppression if feasible
- Emerging therapies include adoptive virus-specific T-cell therapy 8
Infectious Hemorrhagic Cystitis
For bacterial, fungal, or parasitic causes 9:
- Obtain urine culture before initiating empiric antibiotics
- Treat according to culture results and susceptibility patterns
- Consider unusual pathogens (TB, schistosomiasis) in appropriate clinical contexts
Critical Pitfalls to Avoid
- Do not delay catheter placement: Small-bore catheters will obstruct with clots; use ≥22 Fr three-way catheter immediately
- Do not use formalin as first-line therapy: Its caustic effects are irreversible; exhaust other options first
- Do not forget upper tract protection: Before formalin instillation, place ureteral catheters or nephrostomy tubes to prevent reflux
- Do not overlook malignancy: Always exclude bladder cancer as the cause of hematuria, especially in radiation cystitis patients
- Do not continue ineffective therapy: If bleeding persists after 48-72 hours of conservative management, escalate promptly to avoid transfusion-related complications